Neurizon Therapeutics Limited has released a press release.
Reformulation of MPL into tablet form for upcoming trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4C & Company Update - June 18
- Epichem gains prestigious international ISO accreditation
- Epichem Awarded Major US Drug Discovery Contract Extension
- MPL successfully reformulated for canine clinical trials
- Chief Executive Officer resigns
Later from Neurizon Therapeutics
- Olivia Newton-John Cancer Reseach Institute collaboration
- PharmAust Progresses Monepantel Tablet Program for Cancer
- PharmAust Develops GMP Method for Monepantel Analogues
- Appendix 4C & Company Update - Sep 2018
- GMP Tablet Manufacture Commences for Canine Clinical Trials
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics